Leukemia stem cells in 2010: Current understanding and future directions

被引:53
作者
Becker, Michael W. [1 ]
Jordan, Craig T. [1 ]
机构
[1] Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Div Hematol Oncol, Rochester, NY 14642 USA
关键词
Acute myelogenous leukemia; Leukemic stem cell; Genetic heterogeneity; Flow cytometry; Xenotransplant; ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; NORMAL HEMATOPOIETIC-CELLS; IMMUNE-DEFICIENT MICE; CELLULAR PROLIFERATION; INITIATING CELLS; NOD/SCID MICE; BLAST-CRISIS; ENGRAFTMENT; EXPRESSION;
D O I
10.1016/j.blre.2010.11.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myeloid leukemias are clonal disorders originating in a primitive multipotential hematopoietic cell and characterized by aberrant proliferation, differentiation and maturation of leukemic progenitors and precursor cells. These diseases are the result of multiple genetic and epigenetic events, although the nature and number of events vary widely among patients. For over four decades, studies have identified sub-populations of leukemic cells possessing different functional capabilities. Investigators have struggled to understand the origin and significance of this heterogeneity. The stem cell model for myeloid malignancies has offered one potential explanation. Since 1994, experimental data supporting the presence of leukemia stem cells has been reported and validated in numerous studies. We will review the history of the model, data from the past decade supporting the stem cell model for myeloid malignancies, more recent data regarding patient specific variability in leukemic stem cell surface antigen phenotype and the impact the stem cell model has on the care of patients with myeloid malignancies. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:75 / 81
页数:7
相关论文
共 67 条
[1]   Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation [J].
Abrahamsson, Annelie E. ;
Geron, Ifat ;
Gotlib, Jason ;
Dao, Kim-Hien T. ;
Barroga, Charlene F. ;
Newton, Isabel G. ;
Giles, Francis J. ;
Durocher, Jeffrey ;
Creusot, Remi S. ;
Karimi, Mobin ;
Jones, Carol ;
Zehnder, James L. ;
Keating, Armand ;
Negrin, Robert S. ;
Weissman, Irving L. ;
Jamieson, Catriona H. M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (10) :3925-3929
[2]   ALTERATIONS IN THE P53 GENE AND THE CLONAL EVOLUTION OF THE BLAST CRISIS OF CHRONIC MYELOCYTIC-LEUKEMIA [J].
AHUJA, H ;
BARELI, M ;
ADVANI, SH ;
BENCHIMOL, S ;
CLINE, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (17) :6783-6787
[3]   Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice [J].
Ailles, LE ;
Gerhard, B ;
Kawagoe, M ;
Hogge, DE .
BLOOD, 1999, 94 (05) :1761-1772
[4]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[5]   ISOLATION OF A CANDIDATE HUMAN HEMATOPOIETIC STEM-CELL POPULATION [J].
BAUM, CM ;
WEISSMAN, IL ;
TSUKAMOTO, AS ;
BUCKLE, AM ;
PEAULT, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :2804-2808
[6]   Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment [J].
Bhatia, R ;
Holtz, M ;
Niu, N ;
Gray, R ;
Snyder, DS ;
Sawyers, CL ;
Arber, DA ;
Slovak, ML ;
Forman, SJ .
BLOOD, 2003, 101 (12) :4701-4707
[7]   Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice [J].
Bonnet, D ;
Bhatia, M ;
Wang, JCY ;
Kapp, U ;
Dick, JE .
BONE MARROW TRANSPLANTATION, 1999, 23 (03) :203-209
[8]  
Christianson SW, 1997, J IMMUNOL, V158, P3578
[9]  
CIVIN CI, 1984, J IMMUNOL, V133, P157
[10]  
CLARKSON B, 1970, CANCER, V26, P1, DOI 10.1002/1097-0142(197007)26:1<1::AID-CNCR2820260102>3.0.CO